Amgen shares surged to a 52-week peak on Friday, closing up 4.49% at $384.32, as the Dow Jones Industrial Average crossed the 50,000 threshold for the first time. The biotech giant's rally was fueled by robust quarterly earnings and a newly declared dividend, though looming payer pressure on a key drug and delayed economic data present near-term tests for investors.
Market Momentum and Earnings Strength
The broader market rally provided a tailwind, with the Dow gaining 2.47% to finish at 50,115.67, while the S&P 500 and Nasdaq Composite advanced 1.97% and 2.18%, respectively. Amgen's performance stood out, driven by its fourth-quarter results, which showcased a 9% year-over-year revenue increase to $9.9 billion and adjusted earnings of $5.29 per share, both exceeding analyst forecasts. For the full year 2026, management issued guidance projecting adjusted earnings per share between $21.60 and $23.00 on revenue of $37 billion to $38.4 billion.
Dividend Declaration and Record Date
Supporting shareholder returns, Amgen's board approved a quarterly cash dividend of $2.52 per share, payable on March 6 to shareholders of record as of February 13. This income component adds to the stock's appeal amid the current growth narrative.
Prolia Faces Payer Pressure
Despite the positive momentum, Amgen confronts a significant commercial challenge. CVS Health's pharmacy benefit manager, Caremark, will remove Amgen's osteoporosis drug Prolia from certain preferred formulary lists starting April 1, opting for lower-cost biosimilar alternatives. This decision follows the expiration of key U.S. patents in 2025. Prolia generated approximately $4.4 billion in global sales that year, and its exclusion from major formularies could accelerate revenue erosion, a risk that may not be fully priced into the stock.
Obesity Pipeline in Focus
Investor sentiment in the biopharma sector remains heavily influenced by the competitive obesity drug market, currently dominated by Novo Nordisk and Eli Lilly. On its earnings call, Amgen commercial chief Murdo Gordon highlighted dissatisfaction with existing weekly GLP-1 therapies and framed the company's investigational candidate MariTide as a "paradigm-changing opportunity." Success in this high-stakes arena is critical for Amgen's long-term growth trajectory.
Upcoming Economic Data and Market Implications
Traders are awaiting a backlog of key U.S. economic reports, postponed from earlier in the month. The January employment report from the Bureau of Labor Statistics is now scheduled for release on Wednesday, February 11, followed by the Consumer Price Index (CPI) for January on Friday, February 13 at 8:30 a.m. ET. These inflation and labor market readings will heavily influence Treasury yields and Federal Reserve interest rate expectations, potentially driving volatility across equity markets.
The confluence of Amgen's dividend record date on February 13, situated between the jobs and CPI data releases, adds a layer of technical consideration for the stock. Monday's trading session will be scrutinized for whether the breakout can sustain itself without the buoyant momentum of Friday's broad market advance.
Analyst commentary reflects cautious optimism. A Citi note suggested the company's 2026 guidance implies "modest upside." The central question for investors is whether Amgen's breakout represents a sustainable re-rating based on its pipeline and financials, or a tactical move within a bullish market cycle that faces immediate tests from drug pricing pressures and macroeconomic crosscurrents.
